Insights in the chemical components of liposomes responsible for P-glycoprotein inhibition

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 10, Issue 1, 2014, Pages 77-87

  Kopecka, Joanna ^a   Salzano, Giuseppina ^a   Campia, Ivana ^a   Lusa, Sara ^b   Ghigo, Dario ^a   De Rosa, Giuseppe ^b   Riganti, Chiara ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Chemoresistance; Doxorubicin; Liposome; P glycoprotein; Polyethylene glycol

Indexed keywords

ALLOSTERIC INHIBITOR; CHEMICAL COMPONENT; CHEMORESISTANCE; DIAGNOSTIC APPLICATIONS; DOXORUBICIN; P-GLYCOPROTEIN; POLYETHYLENE GLYCOL (PEG); SITE DIRECTED MUTAGENESIS;

AMINO ACIDS; CELLS; GLYCOPROTEINS; LIPOSOMES; OPTIMIZATION; PHOSPHOLIPIDS; POLYETHYLENE GLYCOLS; SURFACE CHARGE;

CYTOLOGY;

ADENOSINE TRIPHOSPHATASE; DISTEAROYL PHOSPHATIDYLETHANOLAMINE; DOXORUBICIN; ETHANOLAMINE; GLYCINE; LIPOSOME; MACROGOL; MEMBRANE PROTEIN; MULTIDRUG RESISTANCE PROTEIN; PHOSPHOLIPID; UNCLASSIFIED DRUG;

ARTICLE; DRUG FORMULATION; EFFUSION; HUMAN; HUMAN CELL; SITE DIRECTED MUTAGENESIS; SURFACE CHARGE; TISSUES; ZETA POTENTIAL;

1,2-DIOLEOYLOXY-3-TRIMETHYLAMMONIUMPROPANCHLORIDE; 1,2-DIPALMITOYL-SN-GLYCERO-3-PHOSPHO-RAC-GLYCEROL; 1,2-DIPALMITOYL-SN-GLYCERO-3-PHOSPHOCHOLINE; BCRP; BREAST CANCER RESISTANCE PROTEIN; CHEMORESISTANCE; DOTAP; DOXORUBICIN; DPPC; DPPG; DSPE-PEG; LIPOSOME; MRPS; MULTIDRUG-RESISTANCE RELATED PROTEINS; P-GLYCOPROTEIN; PEG; PEGYLATED DISTEAROYL-PHOSPHATIDYLETHANOLAMINE; PGP; POLYETHYLENE GLYCOL;

ADENOSINE TRIPHOSPHATASES; DOXORUBICIN; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; HUMANS; LIPOSOMES; NEOPLASMS; P-GLYCOPROTEINS; POLYETHYLENE GLYCOLS; SURFACE PROPERTIES;

EID: 84891012533     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2013.06.013     Document Type: Article

References (29)

1. Markman M. Pegylated liposomal doxorubicin in the treatment of cancers of the breast and ovary. Expert Opin Pharmacother 2006, 7:1469-1474.
2. Jabr-Milane L.S., van Vlerken L.E., Yadav S., Amiji M.M. Multi-functional nanocarriers to overcome tumour drug resistance. Cancer Treat Rev 2008, 34:592-602.
3. Patel N.R., Rathi A., Mongayt D., Torchilin V.P. Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes. Int J Pharm 2011, 416:296-299.
4. Chen Y., Bathura S.R., Li J., Huang L. Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer. J Biol Chem 2010, 285:22639-22650.
5. Guo L., Fan L., Pang Z., Ren J., Ren Y., Li J., et al. TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes. J Control Release 2011, 154:93-102.
6. Rahman A., Husain S.R., Siddiqi J., Verma M., Agresti M., Center M., et al. Liposome-mediated modulation of multidrug resistance in human HL-60 leukemia cells. J Natl Cancer Inst 1992, 84:1909-1915.
7. Thierry A.R., Dritschilo A., Rahman A. Effect of liposome on P-glycoprotein function in multidrug-resistant cells. Biochem Biophys Res Commun 1992, 187:1098-1105.
8. Zalipsky S., Saad M., Kiwan R., Ber E., Yui N., Minko T. Antitumor activity of new liposomal prodrug of mitomycin C in multidrug resistant solid tumors. Insights of the mechanism of action. J Drug Target 2007, 15:518-530.
9. Riganti C., Voena C., Kopecka J., Corsetto P., Montorfano G., Enrico E., et al. Liposome-encapsulated doxorubicin reverses drug-resistance by inhibiting P-glycoprotein in human cancer cells. Mol Pharm 2011, 8:683-700.
10. Safa A.R., Sterns R.K., Choi K., Agresti M., Tamai I., Metha N.D., et al. Molecular basis of preferential resistance to colchicine in multidrug-resistant human cells conferred by Gly-185 Val-185 substitution in P-glycoprotein. Proc Natl Acad Sci USA 1990, 87:7225-7229.
11. Doublier S., Riganti C., Voena C., Costamagna C., Aldieri E., Pescarmona G., et al. RhoA silencing reverts the resistance to doxorubicin in human colon cancer cells. Mol Cancer Res 2008, 6:1607-1620.
12. Riganti C., Miraglia E., Viarisio D., Costamagna C., Pescarmona G., Ghigo D., et al. Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux. Cancer Res 2005, 65:516-525.
13. Rao U.S. Mutation of glycine 185 to valine alters the ATPase function of the human P-glycoprotein expressed in Sf9 cells. J Biol Chem 1995, 270:6686-6690.
14. Lockman P.R., Koziara J.M., Mumper R.J., Allen D.D. Nanoparticle surface charges alter blood-brain barrier integrity and permeability. J Drug Target 2004, 12:635-641.
15. Dadashzadeh S., Mirahmadi N., Babaei M.H., Vali A.M. Peritoneal retention of liposomes: effects of lipid compostion, PEG coating and liposome charge. J Control Release 2010, 148:177-186.
16. Jallouli Y., Paillard A., Chang J., Sevin E., Betbeder D. Influence of surface charge and inner composition of porous nanoparticles to cross blood-brain barrier in vitro. Int J Pharm 2007, 344:103-109.
17. Zelphati O., Szoka F.C. Mechanism of oligonucleotide release from cationic liposomes. Proc Natl Acad Sci USA 1996, 93:11493-11498.
18. Marcusson E.G., Bhat B., Manoharan M., Bennett C.F., Dean N.M. Phosphorothioate oligodeoxyribonucleotides dissociate from cationic lipids before entering the nucleus. Nucleic Acids Res 1998, 26:2016-2023.
19. Chernenko T., Sawant R.R., Miljkovic M., Quintero L., Diem M., Torchilin V. Raman microscopy for noninvasive imaging of pharmaceutical nanocarriers: intracellular distribution of cationic liposomes of different composition. Mol Pharm 2012, 9:930-936.
20. Gayet L., Dayan G., Barakat S., Labialle S., Michaud M., Cogne S., et al. Control of P-glycoprotein activity by membrane cholesterol amounts and their relation to multidrug resistance in human CEM leukemia cells. Biochemistry 2005, 44:4499-4509.
21. Barta C.A., Sachs-Barrable K., Feng F., Wasan K.M. Effects of monoglycerides on P-glycoprotein: modulation of the activity and expression in Caco-2 cell monolayers. Mol Pharm 2008, 5:863-875.
22. Klappe K., Hummel I., Hoekstra D., Kok J.W. Lipid dependence of ABC transporter localization and function. Chem Phys Lipids 2009, 161:57-64.
23. Shen Q., Lin Y., Handa T., Doi M., Sugie M., Wakayama K., et al. Modulation of intestinal P-glycoprotein function by polyethylene glycols and their derivatives by in vitro transport and in situ absorption studies. Int J Pharm 2006, 313:49-56.
24. Shen Q., Li W., Lin Y., Katsumi H., Okada N., Sakane T., et al. Modulating effect of polyethylene glycol on the intestinal transport and absorption of prednisolone, methylprednisolone and quinidine in rats by in-vitro and in-situ absorption studies. J Pharm Pharmacol 2008, 60:1633-1641.
25. Wang J., Qu H., Jin L., Zeng W., Qin L., Zhang F., et al. Pegylated phosphotidylethanolamine inhibiting P-glycoprotein expression and enhancing retention of doxorubicin in MCF7/ADR cells. J Pharm Sci 2011, 100:2267-2277.
26. Kang D.I., Kang H.K., Gwak H.S., Han H.K., Lim S.J. Liposome composition is important for retention of liposomal rhodamine in P-glycoprotein-overexpressing cancer cells. Drug Deliv 2009, 16:261-267.
27. Li M., Si L., Pan H., Rabba A.K., Yan F., Qiu J., et al. Excipients enhance intestinal absorption of gancyclovir by P-gp inhibition: assessed in vitro by everted gut sac and in situ by improbe intestinal perfusion. Int J Pharm 2011, 403:37-45.
28. Zabaleta V., Ponchel G., Salman H., Agüeros M., Vauthier C., Irache J.M. Oral administration of paclitaxel with pegylated poly(anhydride) nanoparticles: Permeability and pharmacokinetic study. Eur J Pharm Biopharm 2012, 81:514-523.
29. Omote H., Figler R.A., Polar M.K., Al-Shawi M.K. Improved energy coupling of human P-glycoprotein by the glycine 185 to valine mutation. Biochemistry 2004, 43:3917-3928.